iX Biopharma Ltd. (SG:42C)
Singapore Market

iX Biopharma Ltd. (42C) Financial Statements


iX Biopharma Ltd. Financial Overview

iX Biopharma Ltd.'s market cap is currently ―. The company's EPS TTM is S$-0.012; its P/E ratio is -3.49; iX Biopharma Ltd. is scheduled to report earnings on February 9, 2024, and the estimated EPS forecast is S$―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 21Dec 20Dec 19Sep 19Jun 19
Income Statement-
Total Revenue--S$ 174.00KS$ 120.00KS$ 129.00K
Gross Profit--S$ -160.00KS$ -235.00KS$ -214.00K
EBIT--S$ -2.36MS$ -3.28MS$ -3.42M
EBITDA--S$ -2.10MS$ -3.02MS$ -3.25M
Net Income Common Stockholders--S$ -2.42MS$ -3.35MS$ -3.77M
Balance Sheet-
Cash, Cash Equivalents and Short-Term InvestmentsS$ 6.21MS$ 10.09MS$ 10.78MS$ 13.72MS$ 15.87M
Total AssetsS$ 18.86MS$ 23.41MS$ 21.29MS$ 24.03MS$ 26.69M
Total DebtS$ 4.24MS$ 4.55MS$ 4.12MS$ 4.22MS$ 3.83M
Net DebtS$ -1.97MS$ -5.53MS$ -6.66MS$ -9.51MS$ -12.04M
Total LiabilitiesS$ 7.15MS$ 6.97MS$ 6.18MS$ 6.41MS$ 6.19M
Stockholders EquityS$ 11.71MS$ 16.45MS$ 15.12MS$ 17.62MS$ 20.50M
Cash Flow-
Free Cash Flow--S$ -2.75MS$ -1.88MS$ -2.11M
Operating Cash Flow--S$ -2.52MS$ -1.70MS$ -1.91M
Investing Cash Flow--S$ -227.00KS$ -181.00KS$ 443.00K
Financing Cash Flow--S$ -199.00KS$ -201.00KS$ -1.26M
Currency in SGD

iX Biopharma Ltd. Earnings and Revenue History

iX Biopharma Ltd. Debt to Assets

iX Biopharma Ltd. Cash Flow

iX Biopharma Ltd. Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis